FDA Acne Product Registration Requirements
The acne monograph, eligible actives and concentrations, the benzoyl peroxide benzene concern, and the registration requirements.
Key Takeaways
- OTC acne products are OTC drugs — under the acne monograph (21 CFR 333.310 / M006).
- Eligible actives — benzoyl peroxide 2.5–10%, salicylic acid 0.5–2%, sulfur 3–10%.
- "Treats acne" = drug — not a cosmetic; the claim controls.
- Benzoyl peroxide → benzene — degrades with heat; 2025 recalls; test for it.
- Full OTC apparatus — registration, NDC listing, Drug Facts, cGMP, OMUFA, U.S. Agent.
- Contaminant testing for BPO — now a real cGMP/quality expectation.
Why Acne Products Are OTC Drugs
An acne product's purpose — to treat or prevent acne — is a drug claim, so OTC acne products are regulated as OTC drugs under the acne monograph (21 CFR 333.310 / OTC Monograph M006). Claims like "treats acne," "clears breakouts," and "prevents pimples" put a product squarely in drug territory.
Eligible Actives & Concentrations
| Active ingredient | Permitted concentration |
|---|---|
| Benzoyl peroxide | 2.5% – 10% |
| Salicylic acid | 0.5% – 2% |
| Sulfur | 3% – 10% |
| Sulfur + resorcinol / resorcinol monoacetate | Sulfur 3–8% in the permitted combination |
Benzoyl Peroxide & Benzene
Benzoyl peroxide (BPO) is the most-used acne active — but it can degrade to form benzene, a known carcinogen, especially when exposed to heat or in older/expired product.
- FDA tested 95 BPO acne products in March 2025 — most had undetectable or low benzene, but several were recalled at retail for elevated levels
- FDA called the cancer risk from the levels found "very low" — but the episode reset expectations for the category
- Test for benzene/contaminants — finished-product and stability testing is now a defensible cGMP practice for BPO
- Control heat & storage — formulate, package, and store to limit degradation (room temperature or cooler); respect expiry
Requirements & Drug Facts
- Drug establishment registration — 21 CFR Part 207, with DUNS/FEI (foreign facilities also need a U.S. Agent)
- Labeler code & NDC listing — each product listed in SPL
- Monograph-compliant active — an eligible acne active at a permitted concentration
- Drug Facts label — active & purpose, uses, warnings, directions, inactive ingredients (21 CFR 201.66)
- cGMP + OMUFA + annual renewal — quality manufacturing (21 CFR 211, incl. BPO contaminant testing), the OTC facility fee, and the Oct–Dec renewal
Get Your Acne Product Compliant
FDA Registration Assistance handles the OTC drug side of acne products: drug establishment registration, NDC drug listing (SPL), Drug Facts label and claims review against the acne monograph, active-ingredient and concentration review, U.S. Agent for foreign firms, and import documentation — and we flag the benzoyl peroxide benzene/contaminant considerations — so your product is compliant before you manufacture, label, list, import, or sell.
Contact us at info@fdaregistrationassistance.com or call +1 (928) 275-8333 for a quote. An independent compliance firm serving 1,000+ companies across 135+ countries, with 15+ years of experience.
Frequently Asked Questions — Acne Product Registration
1. Do acne products require FDA registration?
Yes. OTC acne products are regulated as OTC drugs under the acne monograph (21 CFR 333.310, now OTC Monograph M006), because treating or preventing acne is a drug claim. So the manufacturing facility must complete drug establishment registration, each product must be listed with an NDC (SPL), and the product needs a compliant Drug Facts label, cGMP, OMUFA fees, and (for foreign facilities) a U.S. Agent.
2. What active ingredients are allowed in OTC acne products?
The acne monograph permits benzoyl peroxide (2.5–10%), salicylic acid (0.5–2%), and sulfur (3–10%), plus sulfur combined with resorcinol or resorcinol monoacetate. Your product must use a monograph active at a permitted concentration for the acne indication. An active or strength outside the monograph means the monograph pathway isn't available and an NDA would be required.
3. What is the benzene issue with benzoyl peroxide?
Benzoyl peroxide can degrade to form benzene — a known carcinogen — especially when exposed to heat or with older/expired product. In March 2025, FDA tested 95 benzoyl peroxide acne products for benzene; most had undetectable or low levels, but six products were recalled at retail for elevated benzene. FDA characterized the cancer risk from the levels found as very low, but the episode means manufacturers should test for benzene/contaminants and control storage and formulation — it's now a real cGMP and quality expectation for BPO acne products.
4. Does the benzene concern affect how I make or store BPO products?
Yes, in practice. Because benzoyl peroxide can generate benzene under heat, a defensible program includes finished-product and stability testing for benzene, formulation and packaging that limit degradation, and storage/handling controls (room temperature or cooler, avoiding heat, respecting expiry). Dermatology guidance echoes storing BPO products cool and discarding old or heat-exposed ones. Building this into your cGMP and quality file is now part of responsible BPO manufacturing.
5. When is an acne product a cosmetic instead of a drug?
Only if it makes no acne-treatment claim. A cleanser that just cleanses, or a product that claims only to improve the look of skin, can be a cosmetic. But "treats acne," "clears breakouts," "prevents pimples," or using a monograph acne active at a treatment level makes it a drug. Salicylic acid is a good example: as a cosmetic exfoliant claiming to improve appearance it may be a cosmetic, but as an acne treatment it's a drug. The claim controls.
6. What does an acne Drug Facts label require?
A Drug Facts panel (21 CFR 201.66): active ingredient and purpose (acne treatment), uses, warnings, directions, and inactive ingredients. Benzoyl peroxide products carry specific cautions — skin irritation, sun sensitivity, and that the product may bleach hair or dyed fabrics. The label must match the SPL listing and the monograph. Non-compliant labeling is a leading cause of enforcement.
7. What are the FDA requirements to sell an OTC acne product?
Drug establishment registration (21 CFR Part 207) with a DUNS/FEI; a labeler code and NDC drug listing (SPL); a monograph-eligible active at a permitted concentration; a compliant Drug Facts label; cGMP manufacturing (21 CFR 211), including contaminant testing for BPO; OMUFA facility fees; a U.S. Agent for foreign facilities; and annual renewal. It's the standard OTC drug apparatus, with the acne monograph governing actives and claims.
8. Do foreign acne manufacturers need a U.S. Agent?
Yes. A foreign OTC acne establishment must complete drug establishment registration and designate a U.S. Agent (21 CFR 207.69) — the U.S.-based contact for FDA communications and inspections. Without a valid, confirmed U.S. Agent the registration isn't complete, and the establishment's products can be refused at the border.
9. What is drug listing / NDC for an acne product?
Each acne product is listed with FDA and assigned a National Drug Code (NDC), submitted in Structured Product Labeling (SPL) format. The listing captures the active ingredient and strength, dosage form, package, and labeling. Registration covers the facility; listing covers each product; both must be accurate and current, and listing errors are a common cause of delays.
10. Does an acne product need to comply with cGMP?
Yes. As an OTC drug, an acne product must be manufactured under current Good Manufacturing Practice (21 CFR Part 211), supporting consistent potency and quality. For benzoyl peroxide, cGMP now effectively includes controlling and testing for benzene. A product not made under cGMP is considered adulterated and can be detained or recalled.
11. Is there a fee, and does the registration renew?
Yes to both. OTC monograph drug manufacturers — including acne-product makers — pay the annual OMUFA facility fee. And drug establishment registration renews annually, October–December (21 CFR 207.29), with drug listings kept current. A lapse makes the product misbranded and can inactivate the listing, so it's ongoing compliance, not a one-time filing.
12. Can I sell an acne product with retinol or other actives?
Only the monograph actives (benzoyl peroxide, salicylic acid, sulfur, sulfur+resorcinol) can carry an OTC acne treatment claim under the monograph. Ingredients like retinol, azelaic acid, or adapalene are handled differently — adapalene, for instance, is available OTC only through an approved application, not the monograph. If your acne active isn't in the monograph, you're on the NDA path, not the monograph path.
13. What are the most common acne-product compliance mistakes?
Treating an acne treatment as a cosmetic; using an active or concentration outside the monograph; non-compliant Drug Facts labeling (missing BPO cautions); ignoring benzene testing/storage for benzoyl peroxide; skipping establishment registration or NDC listing; and overlooking OMUFA and annual renewal. Most are caught by matching the product to the monograph — and, for BPO, building in contaminant controls — before launch.
14. Does registering an acne product mean it's FDA-approved?
No. Registration identifies the facility, listing identifies the product, and monograph compliance lets you market without an NDA — but none of these is FDA "approval." Claiming an acne product is "FDA-approved" because it's registered or listed is misbranding. It's compliance, not approval.
15. Can imported acne products be detained?
Yes. FDA can detain acne imports that appear misbranded, unregistered, unlisted, made with a non-monograph active, or contaminated (such as benzene in BPO). A compliant Drug Facts label, an eligible active at a permitted strength, contaminant controls, clean registration/listing, and a responsive U.S. Agent are what keep shipments moving.
16. How does FDA Registration Assistance help with acne products?
We handle the OTC drug side: drug establishment registration, NDC drug listing (SPL), Drug Facts label and claims review against the acne monograph, active-ingredient and concentration review, U.S. Agent for foreign firms, and import documentation — and we flag the benzoyl peroxide benzene/contaminant considerations — so your acne product is compliant before you manufacture, label, list, import, or sell. We're an independent compliance firm serving 1,000+ companies across 135+ countries with 15+ years of experience. Contact info@fdaregistrationassistance.com or +1 (928) 275-8333.
